Overview

Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability

Status:
Recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

This is a multi-site, double-blind, parallel group, randomized, placebo-controlled study of 140 participants comparing oral purified cannabidiol isolate (CBD) with placebo in reducing Severe Behavioral Problems (SBP) at 8 week in children aged 6 - 18 years with Intellectual Disability (ID). Eligible participants will be randomized 1:1 to receive either CBD or placebo.

Phase:

Phase 2

Details

Lead Sponsor:

Murdoch Childrens Research Institute

Collaborators:

Deakin University
Monash University
University of Sydney

Treatments:

Cannabidiol
Epidiolex